Women's health deserves better science, therapies and funding.

Urinary incontinence costs Europe over EUR 40 billion annually. Yet it remains a taboo and ventures tackling women's health diseases get just 2–3% of VC funding.

Our CEO Deana Mohr sat down with Precision Valley to discuss:

• Why breaking the silence matters for patients and entrepreneurs

• How to tackle challenges when the path isn't clear

• What Europe needs to change to compete globally in scaling innovation

Read the full interview published by Wirtschaft Regional here:

Interview Precision Valley.

Download • 2.00MB